by Sue Robbins | Nov 17, 2020 | Migraine
Nearly 80% of people taking a new class of medication to prevent migraine say their migraine headaches are “better” since they started taking the drugs, according to a survey conducted by Eli Lilly. Calcitonin gene-related peptide (CGRP) inhibitors prevent migraines...
by Sue Robbins | Nov 12, 2020 | Migraine
Novartis announced positive results from a phase 4 study comparing treatment with erenumab (Aimovig), a calcitonin gene-related peptide (CGRP) receptor antagonist, to topiramate in patients with episodic and chronic migraine. The randomized, double-blind,...
by Sue Robbins | Nov 3, 2020 | Migraine
“Can you draw me a picture of your headache?” may sound like an unusual question – but drawings of headache pain provide plastic surgeons with valuable information on which patients are more or less likely to benefit from surgery to alleviate migraine headaches....
by Sue Robbins | Nov 2, 2020 | Migraine
Treatment with fremanezumab, the fully humanized IgG2?a monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduced the number of headache or migraine days experienced before therapy. These findings, from a pooled analysis of...
by Sue Robbins | Oct 28, 2020 | Migraine
Fewer than one in three people with migraine took guideline-recommended prescription medication, data presented at the American Headache Society (AHS) annual scientific meeting showed. About 28% of survey respondents with mild to severe migraine-related...
